The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease

Secretory leukocyte proteinase inhibitor and elafin are two low-molecular-mass elastase inhibitors that are mainly synthesized locally at mucosal sites. It is thought that their physicochemical properties allow them to efficiently inhibit target enzymes, such as neutrophil elastase, released into the interstitium. Historically, in the lung, these inhibitors were first purified from secretions of patients with chronic obstructive pulmonary disease and cystic fibrosis. This suggested that they might be important in controlling excessive neutrophil elastase release in these pathologies. They are upregulated by 'alarm signals' such as bacterial lipopolysaccharides, and cytokines such as interleukin-1 and tumor necrosis factor and have been shown to be active against Gram-positive and Gram-negative bacteria, so that they have joined the growing list of antimicrobial 'defensin-like' peptides produced by the lung. Their site of synthesis and presumed functions make them very attractive candidates as potential therapeutic agents under conditions in which the excessive release of elastase by neutrophils might be detrimental. Because of its natural tropism for the lung, the use of adenovirus-mediated gene transfer is extremely promising in such applications.

[1]  B. Rasche,et al.  An elastase-specific inhibitor from human bronchial mucus. Isolation and characterization. , 1981, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[2]  An elastase-specific inhibitor from human bronchial mucus. Pathogenesis in lung emphysema. , 1983, Respiration; international review of thoracic diseases.

[3]  R. Stockley,et al.  Low molecular mass bronchial proteinase inhibitor and alpha 1-proteinase inhibitor in sputum and bronchoalveolar lavage. , 1984, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[4]  E. Klasen,et al.  Characterization of a low molecular weight anti-elastase isolated from human bronchial secretion. , 1985, Experimental lung research.

[5]  R. Stockley,et al.  Lung lavage fluid from patients with alpha 1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profile. , 1987, Clinical science.

[6]  J. Schröder,et al.  Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. , 1990, The Journal of biological chemistry.

[7]  J. Sallenave,et al.  Purification and characterization of elastase-specific inhibitor. Sequence homology with mucus proteinase inhibitor. , 1991, Biological chemistry Hoppe-Seyler.

[8]  C. Boudier,et al.  The proteinase: mucus proteinase inhibitor binding stoichiometry. , 1992, The Journal of biological chemistry.

[9]  B. Wieringa,et al.  SKALP/elafin: an elastase inhibitor from cultured human keratinocytes. Purification, cDNA sequence, and evidence for transglutaminase cross-linking. , 1993, The Journal of biological chemistry.

[10]  J. Sallenave,et al.  Characterization and gene sequence of the precursor of elafin, an elastase-specific inhibitor in bronchial secretions. , 1993, American journal of respiratory cell and molecular biology.

[11]  M. Jordana,et al.  Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. , 1994, American journal of respiratory cell and molecular biology.

[12]  Y. Izawa,et al.  A morphologic study of lung secretory leukoprotease inhibitor in pneumonia. , 1995, American journal of respiratory and critical care medicine.

[13]  B. Beutler,et al.  Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense. , 1995, The Journal of infectious diseases.

[14]  T. Standiford,et al.  IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. , 1996, Journal of immunology.

[15]  D. Radzioch,et al.  Secretory Leukocyte Protease Inhibitor: A Macrophage Product Induced by and Antagonistic to Bacterial Lipopolysaccharide , 1997, Cell.

[16]  S. Wahl,et al.  Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. , 1997, The Journal of clinical investigation.

[17]  G. Turino,et al.  Atopy, asthma, and emphysema in patients with severe alpha-1-antitrypysin deficiency. , 1997, American journal of respiratory and critical care medicine.

[18]  T. Abe,et al.  Cis-acting region associated with lung cell-specific expression of the secretory leukoprotease inhibitor gene. , 1997, American journal of respiratory cell and molecular biology.

[19]  G. Turino,et al.  Atopy, Asthma, and Emphysema in Patients with Severe α -1-Antitrypysin Deficiency , 1997 .

[20]  M. Jordana,et al.  Adenoviral vector-mediated interleukin-10 expression in vivo: intramuscular gene transfer inhibits cytokine responses in endotoxemia , 1997, Gene Therapy.

[21]  J. Sallenave,et al.  Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils , 1997, Journal of leukocyte biology.

[22]  J. Sallenave,et al.  Adenovirus-mediated expression of an elastase-specific inhibitor (elafin): a comparison of different promoters , 1998, Gene Therapy.

[23]  D. Radzioch,et al.  Lipopolysaccharide-Related Stimuli Induce Expression of the Secretory Leukocyte Protease Inhibitor, a Macrophage-Derived Lipopolysaccharide Inhibitor , 1998, Infection and Immunity.

[24]  A. Lentsch,et al.  Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation. , 1999, The American journal of pathology.

[25]  A. Lentsch,et al.  Inhibition of NF-κB Activation and Augmentation of IκBβ by Secretory Leukocyte Protease Inhibitor during Lung Inflammation , 1999 .

[26]  D. Dripps,et al.  Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma. , 1999, The Journal of pharmacology and experimental therapeutics.

[27]  C. Haslett,et al.  Elafin (elastase‐specific inhibitor) has anti‐microbial activity against Gram‐positive and Gram‐negative respiratory pathogens , 1999, FEBS letters.

[28]  C. Haslett,et al.  Secretory leukocyte proteinase inhibitor is preferentially increased in patients with acute respiratory distress syndrome. , 1999, The European respiratory journal.

[29]  A. Beaudet,et al.  Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Schalkwijk,et al.  The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. , 1999, The Biochemical journal.

[31]  P. Hiemstra,et al.  Recombinant SLPI: Emphysema and Asthma , 1999 .

[32]  C. Vogelmeier,et al.  Transforming growth factor‐β1 is a potent inhibitor of secretory leukoprotease inhibitor expression in a bronchial epithelial cell line , 2000 .

[33]  J. Schalkwijk,et al.  Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins. , 2000, American journal of physiology. Lung cellular and molecular physiology.